WAVEMAN · COMPANY

OBIO · Orchestra Biomed Holdings, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

OBIO

Name: Orchestra BioMed Holdings, Inc. (OBIO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Orchestra BioMed Holdings, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001814114

CLUSTER · 4 INSIDERSC-SUITE BUYING · 2FORM 144 · 3☆ WATCH

INSIDER NET · 180D

-$46.0K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+1169.2%

XBRL, annual

NET MARGIN

-157.4%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$46.0K over 180 days

-$188.8K over 90 days · -$132 of it by a 10%+ holder

more than 65% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

47 funds added or opened last quarter

below 63% of Medical Devices

REVENUE

+1169.2% year over year

the highest in Medical Devices

MARGIN

-157.4% net margin

below 86% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

4.0% of shares outstanding short · 13.4 days to cover · settled 2026-07-31

more than 56% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders have filed intent to sell ($201.4K) and have not sold yet.

47 funds added or opened positions in the latest 13F quarter, of 78 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +85.4%

+85.4%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

4 insiders reported buying shares.

The record shows a net $46.0K sold by insiders over 180 days, 47 funds added last quarter, $201.4K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Orchestra BioMed Holdings, Inc. insiders sold a net $46.0K of stock across 45 Form 4 purchases and sales, with 4 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Sherman Darren

See Remarks

SELL

2026-09-01

15,000.0

$74.1K

Sherman Darren

See Remarks

BUY

2026-08-26

2,000.0

$10.7K

Sherman Darren

See Remarks

SELL

2026-08-03

15,000.0

$61.4K

Sherman Darren

See Remarks

SELL

2026-07-01

15,000.0

$64.0K

Hochman David P

See Remarks

BUY

2026-06-01

5,000.0

$19.1K

45 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 40 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

RTW INVESTMENTS, LP

9,556,063.0 sh

$41.2M

PERCEPTIVE ADVISORS LLC

5,037,906.0 sh

$21.7M

BlackRock, Inc.

2,510,387.0 sh

$10.8M

VANGUARD CAPITAL MANAGEMENT LLC

2,022,916.0 sh

$8.7M

GEODE CAPITAL MANAGEMENT, LLC

1,007,908.0 sh

$4.4M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Sherman Darren

FILED 2026-09-01

$75.3K

Sherman Darren

FILED 2026-08-03

$61.3K

Sherman Darren

FILED 2026-07-01

$64.8K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Simplify Propel Opportunities ETF

$932.4K POSITION · AS OF 2026-03-31

1.3%

Ultra-Small Company Market Fund

$269.9K POSITION · AS OF 2026-03-31

0.2%

iShares Micro-Cap ETF

$428.4K POSITION · AS OF 2026-03-31

0.0%

Invesco Nasdaq Biotechnology ETF

$13.8K POSITION · AS OF 2026-02-28

0.0%

1290 VT Micro Cap Portfolio

$31.2K POSITION · AS OF 2026-03-31

0.0%

Health Sciences Portfolio

$53.2K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$33.5M	$2.6M	$2.8M	$3.5M
OPERATING INCOME	$-51.8M	$-64.3M	$-51.5M	$-32.7M
NET INCOME	$-52.7M	$-61.0M	$-49.1M	$-33.6M
EPS (DILUTED)	-1.11	-1.66	-1.48	-2.24
OPERATING CASH FLOW	$-49.0M	$-50.6M	$-46.1M	$-29.3M
CASH	$34.7M	$22.3M	$30.6M	$19.8M
LONG-TERM DEBT	$15.0M	$15.0M	—	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE